TNFRSF8 and T-cell non-Hodgkin lymphoma: Brentuximab vedotin is an anti-CD30 antibody–drug conjugate with the anti-microtubule cytotoxin monomethyl auristatin E. It is indicated for the treatment of Hodgkin lymphoma and CD30+ T-cell lymphomas.